Frazier Life Sciences Management, L.P. 13F annual report

Frazier Life Sciences Management, L.P. is an investment fund managing more than $2.13 trillion ran by Steve Bailey. There are currently 48 companies in Mr. Bailey’s portfolio. The largest investments include Newamsterdam Pharma Company and Mirum Pharmaceuticals Inc, together worth $457 billion.

Limited to 30 biggest holdings

$2.13 trillion Assets Under Management (AUM)

As of 8th August 2024, Frazier Life Sciences Management, L.P.’s top holding is 12,226,943 shares of Newamsterdam Pharma Company currently worth over $235 billion and making up 11.0% of the portfolio value. In addition, the fund holds 6,495,392 shares of Mirum Pharmaceuticals Inc worth $222 billion, whose value grew 43.2% in the past six months. The third-largest holding is Krystal Biotech Inc worth $182 billion and the next is Hillevax Inc worth $154 billion, with 10,617,062 shares owned.

Currently, Frazier Life Sciences Management, L.P.'s portfolio is worth at least $2.13 trillion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Frazier Life Sciences Management, L.P.

The Frazier Life Sciences Management, L.P. office and employees reside in Palo Alto, California. According to the last 13-F report filed with the SEC, Steve Bailey serves as the Steve R. Bailey at Frazier Life Sciences Management, L.P..

Recent trades

In the most recent 13F filing, Frazier Life Sciences Management, L.P. revealed that it had opened a new position in Erasca Inc and bought 16,216,216 shares worth $38.3 billion.

The investment fund also strengthened its position in Hillevax Inc by buying 835,590 additional shares. This makes their stake in Hillevax Inc total 10,617,062 shares worth $154 billion.

On the other hand, there are companies that Frazier Life Sciences Management, L.P. is getting rid of from its portfolio. Frazier Life Sciences Management, L.P. closed its position in Alpine Immune Sciences Inc on 15th August 2024. It sold the previously owned 3,131,008 shares for $124 billion. Steve Bailey also disclosed a decreased stake in Vaxcyte by approximately 0.1%. This leaves the value of the investment at $78.5 billion and 1,039,405 shares.

One of the largest hedge funds

The two most similar investment funds to Frazier Life Sciences Management, L.P. are Etf Managers Group and Nicholas Hoffman ,. They manage $2.13 trillion and $2.13 trillion respectively.


Steve Bailey investment strategy

Frazier Life Sciences Management, L.P.’s portfolio is diversified across 2 sectors. Currently, their heaviest sector is Health Care — making up 67.1% of the total portfolio value. The fund focuses on investments in the United States as 56.3% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are small-cap stocks. Stocks with a size of more than $100 million in market cap make up 10% of the total holdings value. On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio. The average market cap of the portfolio companies is close to $879 million.

The complete list of Frazier Life Sciences Management, L.P. trades based on 13F SEC filings

These positions were updated on August 15th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security Shares Owned Value Allocation
Newamsterdam Pharma Company
No change
12,226,943
$234,879,575,000 11.01%
Mirum Pharmaceuticals Inc
No change
6,495,392
$222,077,452,000 10.41%
Krystal Biotech Inc
No change
988,460
$181,520,794,000 8.51%
Hillevax Inc
8.54%
10,617,062
$153,522,717,000 7.20%
Alpine Immune Sciences Inc
Closed
3,131,008
$124,113,157,000
Phathom Pharmaceuticals Inc
No change
10,109,279
$104,125,574,000 4.88%
Rhythm Pharmaceuticals Inc.
8.27%
2,371,304
$97,365,742,000 4.56%
BridgeBio Pharma Inc
6.35%
3,632,604
$92,013,859,000 4.31%
Arcutis Biotherapeutics Inc
No change
8,785,284
$81,703,141,000 3.83%
Disc Medicine Inc
123.55%
1,754,834
$79,090,368,000 3.71%
Vaxcyte, Inc.
8.78%
1,039,405
$78,485,472,000 3.68%
Edgewise Therapeutics Inc
12.94%
3,731,067
$67,196,517,000 3.15%
AnaptysBio Inc
140.70%
2,165,591
$54,269,710,000 2.54%
Apellis Pharmaceuticals Inc
Closed
885,165
$52,029,999,000
Verona Pharma Plc
9.95%
3,314,349
$47,925,487,000 2.25%
KalVista Pharmaceuticals Inc
No change
3,687,867
$43,443,073,000 2.04%
Tarsus Pharmaceuticals, Inc.
11.19%
1,587,527
$43,148,984,000 2.02%
Revolution Medicines Inc
No change
997,455
$38,711,229,000 1.81%
Erasca Inc
Opened
16,216,216
$38,270,270,000 1.79%
Agios Pharmaceuticals Inc
66.67%
871,974
$37,599,519,000 1.76%
Soleno Therapeutics Inc
No change
875,667
$35,727,214,000 1.67%
Aerovate Therapeutics Inc
Closed
1,204,867
$35,627,917,000
Rocket Pharmaceuticals Inc
No change
1,561,230
$33,613,282,000 1.58%
Savara Inc
103.93%
8,157,385
$32,874,262,000 1.54%
Oric Pharmaceuticals, Inc.
No change
4,142,855
$29,289,985,000 1.37%
Structure Therapeutics Inc
Closed
629,194
$26,967,255,000
Cg Oncology Inc
No change
770,000
$24,308,900,000 1.14%
Pepgen Inc
No change
1,502,788
$23,984,496,000 1.12%
Deciphera Pharmaceuticals In
Closed
1,455,837
$22,900,316,000
Merus N.V
50.02%
373,100
$22,076,327,000 1.03%
Trevi Therapeutics, Inc.
No change
7,381,090
$21,995,648,000 1.03%
Silence Therapeutics plc
No change
1,148,591
$21,823,229,000 1.02%
Ultragenyx Pharmaceutical In
Opened
425,000
$17,467,500,000 0.82%
Autolus Therapeutics plc
No change
4,623,324
$16,089,168,000 0.75%
Cerevel Therapeutics Hldng I
No change
393,000
$16,069,770,000 0.75%
Mereo BioPharma Group plc
Opened
4,401,371
$15,844,936,000 0.74%
Adverum Biotechnologies Inc
Closed
1,069,244
$15,119,110,000
Immatics N.v
Opened
1,152,456
$13,391,539,000 0.63%
Tyra Biosciences Inc
No change
832,220
$13,307,198,000 0.62%
Macrogenics Inc
21.81%
3,010,727
$12,795,590,000 0.60%
Applied Therapeutics, Inc.
17.07%
2,286,135
$10,676,250,000 0.50%
Puma Biotechnology Inc
8.74%
3,062,558
$9,983,939,000 0.47%
89bio Inc
No change
1,000,000
$8,010,000,000 0.38%
Elevation Oncology Inc
Opened
2,958,579
$7,988,163,000 0.37%
Cogent Biosciences, Inc.
No change
936,576
$7,895,336,000 0.37%
Acadia Pharmaceuticals Inc
No change
470,338
$7,642,993,000 0.36%
Arvinas Inc
No change
285,331
$7,595,511,000 0.36%
Adverum Biotechnologies Inc
Opened
1,069,244
$7,335,014,000 0.34%
Allogene Therapeutics Inc
No change
2,867,750
$6,681,858,000 0.31%
Intellia Therapeutics Inc
Closed
203,684
$5,603,347,000
An2 Therapeutics Inc
50.40%
2,088,889
$4,491,111,000 0.21%
Design Therapeutics Inc
Opened
1,195,179
$4,003,850,000 0.19%
Immunocore Hldgs Plc
Opened
108,762
$3,685,944,000 0.17%
Gritstone Bio Inc
Closed
1,030,878
$2,649,356,000
Bluebird bio Inc
Closed
1,709,907
$2,188,681,000
Metagenomi Inc
11.95%
245,692
$1,002,423,000 0.05%
Aclaris Therapeutics Inc
No change
264,377
$290,815,000 0.01%
No transactions found
Showing first 500 out of 57 holdings